Monteris Medical Founders to Receive Pioneer in Technology Award

Torchia and Tyc, both from Winnipeg, Manitoba, founded Monteris Medical in 1999 with the sole focus of helping patients who suffer from neurological diseases.

The revolutionary technology they developed – the minimally invasive NeuroBlate System, an MRI-guided, robotically controlled laser ablation surgical device – has been used in nearly 3,000 patients and in more than 80 institutions in the U.S. and Canada to ablate primary brain tumors, metastatic brain tumors, radiation effect and epileptic foci.

The SBMT presents this award to “the trailblazing companies and their CEOs/presidents who have facilitated the development of pioneering technologies through interdisciplinary approaches that have impacted diagnostics, treatment, and healthcare delivery in unprecedented ways.”

Torchia, who currently serves as vice-provost (teaching and learning) at the University of Manitoba in Winnipeg, said the idea for the technology came after a brain biopsy surgery he attended with a neurosurgeon. “I thought at that moment how beneficial it could be to the patient to slide a heat source down the small biopsy tract and affect some kind of change in the tumor,” said Torchia. Torchia and Tyc then began developing concepts and prototypes for laser technology use in the brain for primary tumors, using magnetic resonance imaging (MRI) as a way to monitor the heat.

Tyc, vice president of technology and advanced development at Monteris Medical, said the recognition was gratifying. “We knew then that there was tremendous potential in developing this technology,” commented Tyc. “The minimally invasive approach to the surgery and subsequent short recoveries change the game for patients that otherwise would undergo an open craniotomy or have no other option. Now, we’re looking at the technology’s next phase of development to offer hope to even more people.”

Tyc and Torchia will receive the award at the 17th Annual “Gathering for Cure” Black Tie Awards Gala of Brain Mapping Foundation, March 21 in Los Angeles.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”